Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CStone Pharmaceuticals ( (HK:2616) ) has shared an update.
CStone Pharmaceuticals has appointed veteran accounting and assurance professional Catherine Yen as an independent non-executive director, effective 21 January 2026, and named her chairperson of the compensation committee as well as a member of the audit and nomination committees. Yen, a former Ernst & Young China practice partner with more than 35 years of experience and strong credentials in IPOs, M&A, and talent strategy, is expected to strengthen CStone’s corporate governance and oversight as the company continues to navigate capital markets and regulatory expectations. Concurrently, independent non-executive director Anthony Wu has resigned from the board and its key committees due to other commitments, prompting this refresh in the company’s board and committee composition.
The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company listed on the Hong Kong Stock Exchange that focuses on the development and commercialization of innovative oncology therapies for patients in China and global markets.
Average Trading Volume: 9,614,225
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.39B
See more insights into 2616 stock on TipRanks’ Stock Analysis page.